\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ initial\\ exam\\,\\ the\\ patient\\ had\\ some\\ confusion\\ and\\ decreased\\ orientation\\ to\\ her\\ surroundings\\.\\ cranial\\ nerves\\ 2\\ through\\ 12\\ were\\ intact\\ bilaterally\\,\\ with\\ pupils\\ being\\ equal\\,\\ round\\ and\\ reactive\\ to\\ light\\ and\\ an\\ oropharynx\\ appearing\\ moist\\ and\\ clear\\ of\\ any\\ lesions\\;\\ jugular\\ venous\\ distension\\ was\\ not\\ noted\\.\\ chest\\ examination\\ revealed\\ an\\ elevated\\ heart\\ rate\\ of\\ greater\\ than\\ 95\\,\\ tachypnea\\ of\\ over\\ 20\\ breaths\\ per\\ minute\\ and\\ bilateral\\ rhonci\\ in\\ the\\ anterior\\ lung\\ fields\\.\\ abdominal\\ examination\\ was\\ unremarkable\\,\\ including\\ a\\ negative\\ hepatojugular\\ reflex\\,\\ and\\ the\\ lower\\ extremities\\ were\\ non\\-edematous\\ bilaterally\\.\\ the\\ patient\\ was\\ placed\\ on\\ 3\\ liters\\ of\\ oxygen\\ via\\ nasal\\ cannula\\ and\\ was\\ saturating\\ well\\ at\\ 96\\%\\ on\\ pulse\\ oximetry\\.\\ persistent\\ confusion\\ and\\ tachypnea\\,\\ however\\,\\ prompted\\ intubation\\ with\\ mechanical\\ ventilation\\.\ \(0\)\
\-\ \\*\\ following\\ the\\ above\\-described\\ plain\\ film\\ of\\ the\\ chest\\,\\ the\\ patient\\ underwent\\ bronchoscopy\\,\\ which\\ confirmed\\ diffuse\\ alveolar\\ hemorrhage\\ as\\ being\\ causative\\ of\\ the\\ abnormalities\\ seen\\ on\\ imaging\\.\\ moreover\\,\\ nursing\\ staff\\ noted\\ the\\ patient\\ to\\ be\\ anuric\\ with\\ a\\ serum\\ potassium\\ of\\ 7\\.3\\,\\ creatinine\\ of\\ 22\\.81\\,\\ but\\ no\\ evidence\\ of\\ structural\\ kidney\\ disease\\ on\\ renal\\ ultrasonography\\.\\ to\\ investigate\\ for\\ potential\\ autoimmune\\ vasculitis\\,\\ further\\ studies\\ were\\ performed\\,\\ which\\ included\\ serum\\ c3\\ of\\ 128\\,\\ c4\\ of\\ 104\\,\\ p\\-anca\\ staining\\ pattern\\ and\\ positive\\ anti\\-gbm\\ antibodies\\ of\\ \\>8\\.0\\ ai\\.\\ it\\ is\\ important\\ to\\ note\\ that\\ definitive\\ diagnosis\\ would\\ require\\ a\\ kidney\\ biopsy\\ with\\ demonstration\\ of\\ a\\ linear\\ immunofluorescence\\ pattern\\.\\ the\\ patient\\,\\ however\\,\\ declined\\ to\\ have\\ a\\ biopsy\\ performed\\ and\\ instead\\ opted\\ for\\ comfort\\ care\\.\ \(0\)\
\-\ the\\ patient\\ was\\ started\\ methylprednisolone\\ for\\ goodpasture\\ disease\\.\\ she\\ completed\\ 3\\ days\\ of\\ intravenous\\ methylprednisolone\\,\\ 1\\ gram\\ daily\\,\\ and\\ was\\ then\\ changed\\ to\\ both\\ prednisone\\,\\ 80\\ mg\\ daily\\ by\\ mouth\\,\\ and\\ cyclophosphamide\\,\\ 100\\ mg\\ daily\\ by\\ mouth\\,\\ both\\ of\\ which\\ she\\ was\\ given\\ for\\ a\\ total\\ of\\ 5\\ days\\.\\ simultaneously\\ with\\ cyclophosphamide\\ and\\ prednisone\\,\\ the\\ patient\\ completed\\ 5\\ days\\ of\\ plasmapharesis\\,\\ after\\ which\\ she\\ opted\\ for\\ comfort\\ care\\,\\ as\\ noted\\ above\\.\ \(0\)\
\-\ chest\\ x\\-ray\\ revealed\\ multifocal\\ patchy\\ and\\ nodular\\ opacities\\ throughout\\ both\\ lungs\\.\\ these\\ findings\\,\\ initially\\,\\ were\\ reported\\ to\\ be\\ consistent\\ with\\ either\\ multifocal\\ bronchopneumonia\\ or\\ underlying\\ malignancy\\ of\\ lungs\\,\\ either\\ from\\ primary\\ or\\ metastatic\\ disease\\.\\ another\\ condition\\ that\\ would\\ explain\\ these\\ findings\\,\\ although\\ less\\ common\\,\\ would\\ be\\ diffuse\\ alveolar\\ hemorrhage\\ secondary\\ to\\ autoimmune\\ vasculitis\\.\ \(0\)\
\-\ goodpasture\\ syndrome\ \(0\)\
\-\ the\\ differential\\ diagnosis\\ for\\ diffuse\\ alveolar\\ hemorrhage\\ includes\\:\ \(0\)\
\-\ general\\ medical\\ conditions\\:\ \(0\)\
\-\ pneumonia\ \(272\)\
\-\ malignancy\ \(256\)\
\-\ acute\\ respiratory\\ distress\\ syndrome\ \(0\)\
\-\ pulmonary\\ toxicity\\ from\\ cytotoxic\\ therapy\ \(0\)\
\-\ occurring\\ in\\ the\\ setting\\ of\\ pathologic\\ capilaritis\\:\ \(0\)\
\-\ immune\\ complex\\-mediated\\ vasculitis\\ \\(primary\\)\ \(0\)\
\-\ \\-\\>goodpasture\\ syndrome\ \(0\)\
\-\ \\-\\>henoch\\-schonlein\\ purpura\ \(0\)\
\-\ vasculitis\\ \\(secondary\\)\ \(0\)\
\-\ \\-\\>antiphospholipid\\ antibody\\ syndrome\ \(0\)\
\-\ \\-\\>dermatomyositis\\,\\ polymyositis\ \(0\)\
\-\ \\-\\>mixed\\ connective\\ tissue\\ disease\ \(0\)\
\-\ \\-\\>systemic\\ lupus\\ erythematosus\ \(0\)\
\-\ idiopathic\\ small\\ vessel\\ vasculitis\\ \\(primary\\)\ \(0\)\
\-\ \\-\\>churg\\-strauss\\ syndrome\ \(0\)\
\-\ \\-\\>microscopic\\ polyangitis\ \(0\)\
\-\ \\-\\>wegner\\'s\\ granulomatosis\ \(0\)\
\-\ occurring\\ outside\\ of\\ pathologic\\ capilaritis\\:\ \(0\)\
\-\ coagulopathy\\ \\(secondary\\ to\\ anti\\-platelet\\ therapy\\ or\\ dic\\,\\ for\\ example\\)\ \(0\)\
\-\ goodpasture\\ syndrome\ \(0\)\
\-\ idiopathic\\ pulmonary\\ hemosiderosis\ \(3\)\
\-\ reference\\:\\ park\\ ms\\ \\(2013\\)\\.\\ diffuse\\ alveolar\\ hemorrhage\\.\\ tuberc\\ respir\\ dis\\ \\(seoul\\)\\.\\ 74\\(4\\)\\:151\\-162\\.\ \(0\)\
\-\ the\\ patient\\ presented\\ to\\ the\\ hospital\\ with\\ four\\ weeks\\ of\\ sinusitis\\ and\\ progressive\\ dyspnea\\.\ \(0\)\
\-\ when\\ patients\\ present\\ with\\ multi\\-systemic\\ illness\\,\\ it\\ is\\ critical\\ to\\ evaluate\\ the\\ potential\\ for\\ a\\ single\\ disease\\ entity\\ as\\ being\\ causative\\ of\\ their\\ symptoms\\.\\ this\\ is\\ especially\\ true\\ in\\ the\\ case\\ of\\ diagnoses\\,\\ including\\ goodpasture\\ syndrome\\,\\ that\\ fall\\ under\\ the\\ category\\ of\\ autoimmune\\ vasculitis\\.\\ one\\ 2017\\ \\ study\\,\\ for\\ example\\,\\ described\\ a\\ 73\\ year\\-old\\ male\\ who\\ presented\\ with\\ small\\-volume\\ hemoptysis\\ and\\ went\\ on\\ to\\ develop\\ acute\\ kidney\\ injury\\ while\\ hospitalized\\.\\ he\\ was\\ discharged\\ with\\ diagnoses\\ of\\ both\\ acute\\ tubular\\ injury\\ and\\ interstitial\\ nephritis\\ secondary\\ to\\ the\\ receipt\\ of\\ cephalosporin\\,\\ only\\ to\\ return\\ in\\ two\\ days\\ with\\ diffuse\\ alveolar\\ hemorrhage\\.\\ a\\ kidney\\ biopsy\\ revealed\\ lymphocytic\\ proliferation\\ in\\ vessels\\ of\\ medium\\ size\\ along\\ with\\ non\\-caseating\\ granulomas\\ of\\ the\\ interstitium\\,\\ confirming\\ polyarteritis\\ nodosa\\ as\\ a\\ diagnosis\\Â\\¹\\.\\ the\\ case\\ presented\\ here\\ has\\ a\\ similar\\ teaching\\ point\\,\\ as\\ the\\ patient\\ presented\\ with\\ respiratory\\ distress\\ and\\ kidney\\ injury\\,\\ which\\ were\\ originally\\ considered\\ to\\ be\\ isolated\\ processes\\ but\\ were\\,\\ in\\ fact\\,\\ related\\ by\\ goodpasture\\ syndrome\\.\ \(0\)\
\-\ another\\ important\\ teaching\\ point\\ presented\\ by\\ this\\ case\\ is\\ that\\ of\\ evaluating\\ diffuse\\ alveolar\\ hemorrhage\\ clinically\\.\\ the\\ differential\\ diagnosis\\ for\\ diffuse\\ alveolar\\ hemorrhage\\,\\ already\\,\\ is\\ quite\\ broad\\,\\ and\\ notably\\ includes\\ a\\ variety\\ of\\ diseases\\ that\\ fall\\ under\\ the\\ classification\\ of\\ autoimmune\\ vasculitis\\,\\ including\\ goodpasture\\ syndrome\\,\\ as\\ discussed\\ in\\ this\\ case\\.\\ in\\ 2013\\,\\ a\\ researcher\\ published\\ in\\ tuberculosis\\ and\\ respiratory\\ diseases\\ an\\ algorithmic\\ approach\\ to\\ identifying\\ an\\ underlying\\ diagnosis\\ in\\ the\\ case\\ of\\ patients\\ presenting\\ with\\ diffuse\\ alveolar\\ hemorrhage\\.\\ the\\ first\\ steps\\ include\\ bronchoalveolar\\ lavage\\,\\ with\\ biopsy\\ and\\ culture\\ as\\ indicated\\,\\ and\\ clinical\\ history\\.\\ one\\ arm\\ of\\ the\\ algorithm\\ then\\ points\\ to\\ confirming\\ the\\ diagnosis\\ as\\ being\\ secondary\\ to\\ either\\ infection\\ or\\ malignancy\\,\\ while\\ the\\ other\\ arm\\ involves\\ a\\ full\\ rheumatologic\\ evaluation\\,\\ including\\ tests\\ for\\ antinuclear\\ antibody\\ \\(ana\\)\\,\\ anti\\-neutrophil\\ cytoplasmic\\ antibody\\ \\(anca\\)\\,\\ erythrocyte\\ sedimentation\\ rate\\ \\(esr\\)\\ and\\ even\\ anti\\-glomerular\\ basement\\ membrane\\ \\(gbm\\)\\ antibodies\\.\\ the\\ author\\ ultimately\\ concluded\\,\\ and\\ highlighted\\ using\\ this\\ algorithm\\,\\ that\\ most\\ diffuse\\ alveolar\\ hemorrhage\\ is\\,\\ in\\ fact\\,\\ caused\\ by\\ pulmonary\\ capillaritis\\ in\\ the\\ setting\\ of\\ systemic\\ vasculitis\\,\\ so\\ the\\ aforementioned\\ rheumatologic\\ workup\\ is\\ an\\ almost\\ essential\\ component\\ of\\ making\\ a\\ definitive\\ diagnosis\\Â\\²\\.\\ \ \(0\)\
\-\ another\\ retrospective\\ study\\ in\\ 2016\\ reported\\ similar\\ findings\\ across\\ six\\ clinical\\ cases\\ of\\ diffuse\\ alveolar\\ hemorrhage\\.\\ presenting\\ symptoms\\ varied\\,\\ but\\ included\\ renal\\ dysfunction\\,\\ hemoptysis\\,\\ hematuria\\ and\\ bleeding\\ from\\ mucosal\\ surfaces\\.\\ all\\ six\\ patients\\,\\ however\\,\\ had\\ documented\\ hypoxemia\\,\\ anemia\\ and\\ chest\\ cts\\ that\\ revealed\\ alveolar\\ filling\\ as\\ well\\ as\\ diffuse\\ infiltrates\\.\\ laboratory\\ studies\\ in\\ 5\\ of\\ 6\\ patients\\ revealed\\ elevated\\ c\\-reactive\\ protein\\ and\\ esr\\,\\ positive\\ serum\\ anca\\ in\\ 3\\ of\\ 6\\ cases\\ and\\ positive\\ anti\\-gbm\\ antibodies\\ in\\ 1\\ patient\\.\\ following\\ pathological\\ analysis\\,\\ 2\\ patients\\ with\\ diagnosed\\ with\\ microscopic\\ polyangiitis\\,\\ 2\\ more\\ with\\ granulomatosis\\ with\\ polyangiitis\\,\\ 1\\ with\\ pulmonary\\ veno\\-occlusive\\ disease\\,\\ and\\ 1\\ with\\ goodpasture\\ syndrome\\Â\\³\\.\\ this\\ study\\,\\ again\\,\\ points\\ to\\ an\\ association\\ between\\ diffuse\\ alveolar\\ hemorrhage\\ and\\ vasculitis\\,\\ and\\ to\\ the\\ importance\\ of\\ rheumatologic\\ laboratory\\ studies\\ in\\ evaluating\\ such\\ patients\\.\\ it\\ is\\ worth\\ noting\\,\\ however\\,\\ that\\ larger\\ studies\\ have\\ not\\ been\\ widely\\ conducted\\ in\\ order\\ to\\ test\\ the\\ strength\\ of\\ this\\ association\\,\\ and\\ more\\ research\\ is\\ warranted\\ before\\ the\\ institution\\ of\\ clinical\\ guidelines\\.\ \(0\)\
\-\ diffuse\\ alveolar\\ hemorrhage\\,\\ in\\ summary\\,\\ is\\ a\\ unique\\ clinical\\ entity\\ that\\ often\\ presents\\ in\\ the\\ setting\\ of\\ multi\\-systemic\\ illness\\.\\ its\\ presence\\ radiographically\\,\\ if\\ accompanied\\ by\\ kidney\\ injury\\,\\ should\\ prompt\\ consideration\\ of\\ and\\ workup\\ for\\ goodpasture\\ syndrome\\,\\ along\\ with\\ other\\ types\\ of\\ autoimmune\\ vasculitis\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\	sitkin\\ na\\,\\ bernstein\\ e\\,\\ perazella\\ ma\\ \\(2017\\)\\.\\ atypical\\ case\\ of\\ classical\\ polyarteritis\\ nodosa\\:\\ alveolarhemorrhage\\ and\\ positive\\ antineutrophil\\ cytoplasmic\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ antibody\\.\\ clin\\ nephrol\\.\\ doi\\:10\\.5414\\/cn109156\\;\\ epub\\ ahead\\ of\\ print\\.\ \(0\)\
\-\ 2\\.\\	park\\ ms\\ \\(2013\\)\\.\\ diffuse\\ alveolar\\ hemorrhage\\.\\ tuberc\\ respir\\ dis\\ \\(seoul\\)\\.\\ 74\\(4\\)\\:151\\-162\\.\ \(0\)\
\-\ 3\\.\\	fang\\ f\\,\\ li\\ ym\\,\\ et\\ al\\ \\(2016\\)\\.\\ clinicopathological\\ diagnosis\\ of\\ diffuse\\ alveolar\\ hemorrhage\\.\\ zhonghua\\ yi\\ xue\\ za\\ zhi\\.\\ 96\\(2\\)\\:108\\-12\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ alveolar\\:\\ 0\\.3338383607759835\ \(0\)\
\-\ goodpasture\\:\\ 0\\.27454909364013036\ \(0\)\
\-\ diffuse\\:\\ 0\\.19947369026948827\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.19876320477426496\ \(0\)\
\-\ vasculitis\\:\\ 0\\.19679217529575654\ \(0\)\
\-\ of\\:\\ 0\\.19503832455811163\ \(0\)\
\-\ the\\:\\ 0\\.1565541531766803\ \(0\)\
\-\ and\\:\\ 0\\.14898059102054445\ \(0\)\
\-\ syndrome\\:\\ 0\\.12783755640476555\ \(0\)\
\-\ autoimmune\\:\\ 0\\.11861479956117088\ \(0\)\
\-\ to\\:\\ 0\\.11662734088988423\ \(0\)\
\-\ in\\:\\ 0\\.10550300123597067\ \(0\)\
\-\ antibody\\:\\ 0\\.09694605429871897\ \(0\)\
\-\ with\\:\\ 0\\.09134908336238981\ \(0\)\
\-\ kidney\\:\\ 0\\.0893843108396224\ \(0\)\
\-\ rheumatologic\\:\\ 0\\.08776400567459482\ \(0\)\
\-\ anca\\:\\ 0\\.08776400567459482\ \(0\)\
\-\ as\\:\\ 0\\.0851885638602332\ \(0\)\
\-\ that\\:\\ 0\\.082820110762432\ \(0\)\
\-\ antibodies\\:\\ 0\\.07854483588624629\ \(0\)\
\-\ for\\:\\ 0\\.0771253738723425\ \(0\)\
\-\ systemic\\:\\ 0\\.07527011583108205\ \(0\)\
\-\ patients\\:\\ 0\\.0715742979336946\ \(0\)\
\-\ revealed\\:\\ 0\\.06952047543023429\ \(0\)\
\-\ 2013\\:\\ 0\\.0695012927337951\ \(0\)\
\-\ patient\\:\\ 0\\.06896966766588893\ \(0\)\
\-\ capilaritis\\:\\ 0\\.06782326305710365\ \(0\)\
\-\ tuberc\\:\\ 0\\.06782326305710365\ \(0\)\
\-\ seoul\\:\\ 0\\.06782326305710365\ \(0\)\
\-\ polyangiitis\\:\\ 0\\.06782326305710365\ \(0\)\
\-\ gbm\\:\\ 0\\.06726340091825539\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06595555847020515\ \(0\)\
\-\ were\\:\\ 0\\.06558381450171064\ \(0\)\
\-\ algorithm\\:\\ 0\\.06480874867295325\ \(0\)\
\-\ case\\:\\ 0\\.06391938351556001\ \(0\)\
\-\ secondary\\:\\ 0\\.06284409924330406\ \(0\)\
\-\ respir\\:\\ 0\\.06266991667945716\ \(0\)\
\-\ studies\\:\\ 0\\.06222039660174916\ \(0\)\
\-\ presented\\:\\ 0\\.061828176001603924\ \(0\)\
\-\ methylprednisolone\\:\\ 0\\.061010909697806745\ \(0\)\
\-\ including\\:\\ 0\\.0607017908041246\ \(0\)\
\-\ daily\\:\\ 0\\.060320912761578575\ \(0\)\
\-\ biopsy\\:\\ 0\\.05945618168802745\ \(0\)\
\-\ setting\\:\\ 0\\.059159534248822455\ \(0\)\
\-\ was\\:\\ 0\\.05912160338850613\ \(0\)\
\-\ being\\:\\ 0\\.059106296968031664\ \(0\)\
\-\ is\\:\\ 0\\.05807171022605161\ \(0\)\
\-\ comfort\\:\\ 0\\.05751657030181068\ \(0\)\
\-\ park\\:\\ 0\\.05751657030181068\ \(0\)\
\-\ serum\\:\\ 0\\.05704487087931004\ \(0\)\
\-\ polyarteritis\\:\\ 0\\.05664088791115636\ \(0\)\
\-\ positive\\:\\ 0\\.05589238668218818\ \(0\)\
\-\ opted\\:\\ 0\\.05585756332016026\ \(0\)\
\-\ cytoplasmic\\:\\ 0\\.05585756332016026\ \(0\)\
\-\ injury\\:\\ 0\\.05531187657275608\ \(0\)\
\-\ dis\\:\\ 0\\.054502055917660275\ \(0\)\
\-\ nodosa\\:\\ 0\\.054502055917660275\ \(0\)\
\-\ by\\:\\ 0\\.054029587820215136\ \(0\)\
\-\ teaching\\:\\ 0\\.05390696181756856\ \(0\)\
\-\ clinical\\:\\ 0\\.0537552776882239\ \(0\)\
\-\ days\\:\\ 0\\.053695077547185485\ \(0\)\
\-\ disease\\:\\ 0\\.053406980888363986\ \(0\)\
\-\ causative\\:\\ 0\\.05335599073875007\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.05284304893600986\ \(0\)\
\-\ either\\:\\ 0\\.05259089319510885\ \(0\)\
\-\ another\\:\\ 0\\.05205974229249347\ \(0\)\
\-\ pulmonary\\:\\ 0\\.05170203600847476\ \(0\)\
\-\ 2017\\:\\ 0\\.05148754153350988\ \(0\)\
\-\ respiratory\\:\\ 0\\.050603058064124996\ \(0\)\
\-\ however\\:\\ 0\\.05020384892328471\ \(0\)\
\-\ points\\:\\ 0\\.049348709540013795\ \(0\)\
\-\ an\\:\\ 0\\.0486526408221853\ \(0\)\
\-\ which\\:\\ 0\\.04821093543046415\ \(0\)\
\-\ microscopic\\:\\ 0\\.04768970255836337\ \(0\)\
\-\ malignancy\\:\\ 0\\.047624757620367386\ \(0\)\
\-\ confirming\\:\\ 0\\.04744591982446835\ \(0\)\
\-\ 2016\\:\\ 0\\.04744591982446835\ \(0\)\
\-\ both\\:\\ 0\\.047300105243245946\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.0467591512303816\ \(0\)\
\-\ 96\\:\\ 0\\.0461304918034679\ \(0\)\
\-\ entity\\:\\ 0\\.0461304918034679\ \(0\)\
\-\ confusion\\:\\ 0\\.04536728821869887\ \(0\)\
\-\ would\\:\\ 0\\.045032183616178126\ \(0\)\
\-\ tachypnea\\:\\ 0\\.04484226727883693\ \(0\)\
\-\ diagnoses\\:\\ 0\\.04484226727883693\ \(0\)\
\-\ chest\\:\\ 0\\.0447725848808643\ \(0\)\
\-\ prednisone\\:\\ 0\\.04467518817421297\ \(0\)\
\-\ completed\\:\\ 0\\.04389186358321687\ \(0\)\
\-\ hemoptysis\\:\\ 0\\.04389186358321687\ \(0\)\
\-\ this\\:\\ 0\\.04371880308876612\ \(0\)\
\-\ occurring\\:\\ 0\\.042788404293187504\ \(0\)\
\-\ illness\\:\\ 0\\.04266131218533402\ \(0\)\
\-\ evaluating\\:\\ 0\\.04266131218533402\ \(0\)\
\-\ study\\:\\ 0\\.042426896569937624\ \(0\)\
\-\ example\\:\\ 0\\.042292573446821864\ \(0\)\
\-\ 74\\:\\ 0\\.04217361559280278\ \(0\)\
\-\ mouth\\:\\ 0\\.04182775289468653\ \(0\)\
\-\ multifocal\\:\\ 0\\.041180848778216914\ \(0\)\
\-\ ms\\:\\ 0\\.041180848778216914\ \(0\)\
\-\ fact\\:\\ 0\\.04068168771577632\ \(0\)\
\-\ workup\\:\\ 0\\.0399467978710847\ \(0\)\
\-\ primary\\:\\ 0\\.03911661620378087\ \(0\)\
\-\ diseases\\:\\ 0\\.038964972496682584\ \(0\)\
\-\ esr\\:\\ 0\\.03881323851053613\ \(0\)\
\-\ definitive\\:\\ 0\\.03873851720557038\ \(0\)\
\-\ on\\:\\ 0\\.0384258933654682\ \(0\)\
\-\ association\\:\\ 0\\.03816633439406651\ \(0\)\
\-\ six\\:\\ 0\\.03809781126141724\ \(0\)\
\-\ potential\\:\\ 0\\.03789595160581061\ \(0\)\
\-\ she\\:\\ 0\\.037868739770915316\ \(0\)\
\-\ mg\\:\\ 0\\.0370202692151563\ \(0\)\
\-\ included\\:\\ 0\\.03667440651704005\ \(0\)\
\-\ reactive\\:\\ 0\\.03639799151160697\ \(0\)\
\-\ important\\:\\ 0\\.03592495308833206\ \(0\)\
\-\ fall\\:\\ 0\\.03533769737300753\ \(0\)\
\-\ under\\:\\ 0\\.035106067820834676\ \(0\)\
\-\ point\\:\\ 0\\.0350605954634059\ \(0\)\
\-\ pathologic\\:\\ 0\\.03474984604724703\ \(0\)\
\-\ underlying\\:\\ 0\\.03462054353139062\ \(0\)\
\-\ acute\\:\\ 0\\.034413506308616545\ \(0\)\
\-\ described\\:\\ 0\\.034409914508011764\ \(0\)\
\-\ be\\:\\ 0\\.03440830649250116\ \(0\)\
\-\ distress\\:\\ 0\\.0341647920665245\ \(0\)\
\-\ hepatojugular\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ saturating\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ ai\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ plasmapharesis\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ polyangitis\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ wegner\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ receipt\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ cephalosporin\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ diagnosis\\Â\\¹\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ algorithmic\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ antinuclear\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ diagnosis\\Â\\²\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ syndrome\\Â\\³\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ sitkin\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ perazella\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ alveolarhemorrhage\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ fang\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ ym\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ zhonghua\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ yi\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ xue\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ zhi\\:\\ 0\\.033911631528551825\ \(0\)\
\-\ arm\\:\\ 0\\.033850048464308106\ \(0\)\
\-\ noted\\:\\ 0\\.03372879885162799\ \(0\)\
\-\ presenting\\:\\ 0\\.033222430240009794\ \(0\)\
\-\ includes\\:\\ 0\\.03297864750611477\ \(0\)\
\-\ it\\:\\ 0\\.03256384079754937\ \(0\)\
\-\ surroundings\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ rhonci\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ anuric\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ antiphospholipid\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ dic\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ researcher\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ capillaritis\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ za\\:\\ 0\\.032404374336476624\ \(0\)\
\-\ similar\\:\\ 0\\.03232318298885713\ \(0\)\
\-\ rate\\:\\ 0\\.032137305625765715\ \(0\)\
\-\ pattern\\:\\ 0\\.03166321948511431\ \(0\)\
\-\ but\\:\\ 0\\.03145792116207873\ \(0\)\
\-\ findings\\:\\ 0\\.031396757969125326\ \(0\)\
\-\ immunofluorescence\\:\\ 0\\.03133495833972858\ \(0\)\
\-\ highlighted\\:\\ 0\\.03133495833972858\ \(0\)\
\-\ hypoxemia\\:\\ 0\\.03133495833972858\ \(0\)\
\-\ nephrol\\:\\ 0\\.03133495833972858\ \(0\)\
\-\ clinicopathological\\:\\ 0\\.03133495833972858\ \(0\)\
\-\ lungs\\:\\ 0\\.03129911209744215\ \(0\)\
\-\ laboratory\\:\\ 0\\.0307971117348857\ \(0\)\
\-\ above\\:\\ 0\\.0305954801972627\ \(0\)\
\-\ reported\\:\\ 0\\.0305459152986017\ \(0\)\
\-\ bronchopneumonia\\:\\ 0\\.030505454848903373\ \(0\)\
\-\ basement\\:\\ 0\\.030505454848903373\ \(0\)\
\-\ bernstein\\:\\ 0\\.030505454848903373\ \(0\)\
\-\ antineutrophil\\:\\ 0\\.030505454848903373\ \(0\)\
\-\ ahead\\:\\ 0\\.030505454848903373\ \(0\)\
\-\ care\\:\\ 0\\.030302929382376706\ \(0\)\
\-\ then\\:\\ 0\\.03002145574411875\ \(0\)\
\-\ breaths\\:\\ 0\\.02982770114765338\ \(0\)\
\-\ simultaneously\\:\\ 0\\.02982770114765338\ \(0\)\
\-\ polymyositis\\:\\ 0\\.02982770114765338\ \(0\)\
\-\ or\\:\\ 0\\.029507559253943993\ \(0\)\
\-\ liters\\:\\ 0\\.029254668558198277\ \(0\)\
\-\ cannula\\:\\ 0\\.029254668558198277\ \(0\)\
\-\ hemosiderosis\\:\\ 0\\.029254668558198277\ \(0\)\
\-\ 12\\:\\ 0\\.02899137899042608\ \(0\)\
\-\ elevated\\:\\ 0\\.028911649462123074\ \(0\)\
\-\ investigate\\:\\ 0\\.02875828515090534\ \(0\)\
\-\ steps\\:\\ 0\\.02875828515090534\ \(0\)\
\-\ epub\\:\\ 0\\.02875828515090534\ \(0\)\
\-\ cases\\:\\ 0\\.02852534401371062\ \(0\)\
\-\ along\\:\\ 0\\.0284132608769301\ \(0\)\
\-\ nephritis\\:\\ 0\\.02832044395557818\ \(0\)\
\-\ worth\\:\\ 0\\.02832044395557818\ \(0\)\
\-\ bilaterally\\:\\ 0\\.02828459771329175\ \(0\)\
\-\ oximetry\\:\\ 0\\.02792878166008013\ \(0\)\
\-\ varied\\:\\ 0\\.02792878166008013\ \(0\)\
\-\ moreover\\:\\ 0\\.027574480017064952\ \(0\)\
\-\ differential\\:\\ 0\\.027556142059623093\ \(0\)\
\-\ while\\:\\ 0\\.027408915322637437\ \(0\)\
\-\ published\\:\\ 0\\.027251027958830137\ \(0\)\
\-\ examination\\:\\ 0\\.027138532534381535\ \(0\)\
\-\ purpura\\:\\ 0\\.02695348090878428\ \(0\)\
\-\ erythrocyte\\:\\ 0\\.02695348090878428\ \(0\)\
\-\ print\\:\\ 0\\.02695348090878428\ \(0\)\
\-\ 128\\:\\ 0\\.026677995369375034\ \(0\)\
\-\ nursing\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ staff\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ interstitium\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ lavage\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ aforementioned\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ cts\\:\\ 0\\.02642152446800493\ \(0\)\
\-\ renal\\:\\ 0\\.026410076880712882\ \(0\)\
\-\ dermatomyositis\\:\\ 0\\.0261816119620821\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.0261816119620821\ \(0\)\
\-\ author\\:\\ 0\\.0261816119620821\ \(0\)\
\-\ concluded\\:\\ 0\\.0261816119620821\ \(0\)\
\-\ noting\\:\\ 0\\.0261816119620821\ \(0\)\
\-\ explain\\:\\ 0\\.025956248804014044\ \(0\)\
\-\ notably\\:\\ 0\\.025956248804014044\ \(0\)\
\-\ summary\\:\\ 0\\.025956248804014044\ \(0\)\
\-\ potassium\\:\\ 0\\.02574377076675494\ \(0\)\
\-\ toxicity\\:\\ 0\\.02574377076675494\ \(0\)\
\-\ guidelines\\:\\ 0\\.02574377076675494\ \(0\)\
\-\ classical\\:\\ 0\\.02574377076675494\ \(0\)\
\-\ medium\\:\\ 0\\.025542783785420395\ \(0\)\
\-\ retrospective\\:\\ 0\\.025542783785420395\ \(0\)\
\-\ following\\:\\ 0\\.02544213381961622\ \(0\)\
\-\ declined\\:\\ 0\\.025352108471256886\ \(0\)\
\-\ hospitalized\\:\\ 0\\.025352108471256886\ \(0\)\
\-\ ma\\:\\ 0\\.025352108471256886\ \(0\)\
\-\ from\\:\\ 0\\.02526534505082262\ \(0\)\
\-\ erythematosus\\:\\ 0\\.025170738177299833\ \(0\)\
\-\ performed\\:\\ 0\\.02509005740842368\ \(0\)\
\-\ cytotoxic\\:\\ 0\\.02499780682824171\ \(0\)\
\-\ sedimentation\\:\\ 0\\.02483256390722214\ \(0\)\
\-\ research\\:\\ 0\\.02483256390722214\ \(0\)\
\-\ staining\\:\\ 0\\.024674354770006898\ \(0\)\
\-\ ana\\:\\ 0\\.024674354770006898\ \(0\)\
\-\ 104\\:\\ 0\\.024522604980431673\ \(0\)\
\-\ widely\\:\\ 0\\.024522604980431673\ \(0\)\
\-\ conducted\\:\\ 0\\.024522604980431673\ \(0\)\
\-\ category\\:\\ 0\\.024376807719961036\ \(0\)\
\-\ therapy\\:\\ 0\\.024367453800385613\ \(0\)\
\-\ one\\:\\ 0\\.02428187349126144\ \(0\)\
\-\ ultrasonography\\:\\ 0\\.024236513574679742\ \(0\)\
\-\ surfaces\\:\\ 0\\.024236513574679742\ \(0\)\
\-\ demonstration\\:\\ 0\\.02410132218055179\ \(0\)\
\-\ these\\:\\ 0\\.02394907579023324\ \(0\)\
\-\ minute\\:\\ 0\\.023844851279181685\ \(0\)\
\-\ structural\\:\\ 0\\.023844851279181685\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.023844851279181685\ \(0\)\
\-\ granulomas\\:\\ 0\\.023844851279181685\ \(0\)\
\-\ unique\\:\\ 0\\.023844851279181685\ \(0\)\
\-\ orientation\\:\\ 0\\.023722959912234175\ \(0\)\
\-\ intubation\\:\\ 0\\.023722959912234175\ \(0\)\
\-\ changed\\:\\ 0\\.023722959912234175\ \(0\)\
\-\ essential\\:\\ 0\\.023722959912234175\ \(0\)\
\-\ warranted\\:\\ 0\\.023722959912234175\ \(0\)\
\-\ instead\\:\\ 0\\.023604938773258855\ \(0\)\
\-\ moist\\:\\ 0\\.023490549636166508\ \(0\)\
\-\ identifying\\:\\ 0\\.023490549636166508\ \(0\)\
\-\ prompted\\:\\ 0\\.0233795756151908\ \(0\)\
\-\ critical\\:\\ 0\\.0233795756151908\ \(0\)\
\-\ infiltrates\\:\\ 0\\.0233795756151908\ \(0\)\
\-\ more\\:\\ 0\\.02328777726991959\ \(0\)\
\-\ symptoms\\:\\ 0\\.023204500275567485\ \(0\)\
\-\ oropharynx\\:\\ 0\\.0231670975779317\ \(0\)\
\-\ bronchoscopy\\:\\ 0\\.0231670975779317\ \(0\)\
\-\ accompanied\\:\\ 0\\.0231670975779317\ \(0\)\
\-\ prompt\\:\\ 0\\.02306524590173395\ \(0\)\
\-\ proliferation\\:\\ 0\\.022775435282433643\ \(0\)\
\-\ quite\\:\\ 0\\.022775435282433643\ \(0\)\
\-\ ventilation\\:\\ 0\\.022683644109349435\ \(0\)\
\-\ documented\\:\\ 0\\.022683644109349435\ \(0\)\
\-\ gram\\:\\ 0\\.02259406498847659\ \(0\)\
\-\ already\\:\\ 0\\.02250659380847764\ \(0\)\
\-\ variety\\:\\ 0\\.022421133639418465\ \(0\)\
\-\ membrane\\:\\ 0\\.022255890718398896\ \(0\)\
\-\ clin\\:\\ 0\\.022255890718398896\ \(0\)\
\-\ ultimately\\:\\ 0\\.022175944548320815\ \(0\)\
\-\ importance\\:\\ 0\\.022175944548320815\ \(0\)\
\-\ lupus\\:\\ 0\\.022097681581183654\ \(0\)\
\-\ pathological\\:\\ 0\\.022097681581183654\ \(0\)\
\-\ other\\:\\ 0\\.022024336891034488\ \(0\)\
\-\ distension\\:\\ 0\\.022021032399021482\ \(0\)\
\-\ connective\\:\\ 0\\.022021032399021482\ \(0\)\
\-\ small\\:\\ 0\\.021876648356647325\ \(0\)\
\-\ jugular\\:\\ 0\\.021872318423115603\ \(0\)\
\-\ sinusitis\\:\\ 0\\.021872318423115603\ \(0\)\
\-\ oxygen\\:\\ 0\\.021800134531137792\ \(0\)\
\-\ 73\\:\\ 0\\.021800134531137792\ \(0\)\
\-\ classification\\:\\ 0\\.021800134531137792\ \(0\)\
\-\ creatinine\\:\\ 0\\.021591630148593256\ \(0\)\
\-\ originally\\:\\ 0\\.021591630148593256\ \(0\)\
\-\ consideration\\:\\ 0\\.021394202146593752\ \(0\)\
\-\ making\\:\\ 0\\.021206732829723837\ \(0\)\
\-\ have\\:\\ 0\\.0211862588165433\ \(0\)\
\-\ radiographically\\:\\ 0\\.021146286723410932\ \(0\)\
\-\ had\\:\\ 0\\.021130358498585352\ \(0\)\
\-\ c4\\:\\ 0\\.02108680779640139\ \(0\)\
\-\ pupils\\:\\ 0\\.021028265584435612\ \(0\)\
\-\ mechanical\\:\\ 0\\.021028265584435612\ \(0\)\
\-\ discussed\\:\\ 0\\.021028265584435612\ \(0\)\
\-\ reflex\\:\\ 0\\.020970631040312583\ \(0\)\
\-\ institution\\:\\ 0\\.020970631040312583\ \(0\)\
\-\ fields\\:\\ 0\\.020857975339312038\ \(0\)\
\-\ processes\\:\\ 0\\.020857975339312038\ \(0\)\
\-\ reference\\:\\ 0\\.0207486335263237\ \(0\)\
\-\ patchy\\:\\ 0\\.02064241619650439\ \(0\)\
\-\ across\\:\\ 0\\.02064241619650439\ \(0\)\
\-\ true\\:\\ 0\\.020590424389108457\ \(0\)\
\-\ went\\:\\ 0\\.020590424389108457\ \(0\)\
\-\ dysfunction\\:\\ 0\\.020590424389108457\ \(0\)\
\-\ culture\\:\\ 0\\.020539149732989273\ \(0\)\
\-\ well\\:\\ 0\\.020535264398493628\ \(0\)\
\-\ c3\\:\\ 0\\.020488572712910706\ \(0\)\
\-\ approach\\:\\ 0\\.02034084385788816\ \(0\)\
\-\ equal\\:\\ 0\\.020292877339062595\ \(0\)\
\-\ tests\\:\\ 0\\.020292877339062595\ \(0\)\
\-\ opacities\\:\\ 0\\.020245521875327008\ \(0\)\
\-\ here\\:\\ 0\\.0201987620936104\ \(0\)\
\-\ isolated\\:\\ 0\\.020152583193781298\ \(0\)\
\-\ 95\\:\\ 0\\.020106970920526192\ \(0\)\
\-\ na\\:\\ 0\\.020106970920526192\ \(0\)\
\-\ li\\:\\ 0\\.020106970920526192\ \(0\)\
\-\ pulse\\:\\ 0\\.020017391799653346\ \(0\)\
\-\ mucosal\\:\\ 0\\.01997339893554235\ \(0\)\
\-\ nerves\\:\\ 0\\.0198024560078376\ \(0\)\
\-\ return\\:\\ 0\\.019760920898283244\ \(0\)\
\-\ analysis\\:\\ 0\\.019719844749607484\ \(0\)\
\-\ types\\:\\ 0\\.019719844749607484\ \(0\)\
\-\ protein\\:\\ 0\\.019679217529575656\ \(0\)\
\-\ order\\:\\ 0\\.019599271359497572\ \(0\)\
\-\ develop\\:\\ 0\\.019521008392360414\ \(0\)\
\-\ anemia\\:\\ 0\\.019482486248341292\ \(0\)\
\-\ conditions\\:\\ 0\\.01936925860278519\ \(0\)\
\-\ nasal\\:\\ 0\\.01933226970425347\ \(0\)\
\-\ intravenous\\:\\ 0\\.01933226970425347\ \(0\)\
\-\ interstitial\\:\\ 0\\.01922346134231455\ \(0\)\
\-\ broad\\:\\ 0\\.019152652465566588\ \(0\)\
\-\ almost\\:\\ 0\\.01904890563070862\ \(0\)\
\-\ larger\\:\\ 0\\.018981315520835505\ \(0\)\
\-\ again\\:\\ 0\\.018914932441943533\ \(0\)\
\-\ hematuria\\:\\ 0\\.018753982903843766\ \(0\)\
\-\ dyspnea\\:\\ 0\\.018660655316754836\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.018660655316754836\ \(0\)\
\-\ vessel\\:\\ 0\\.01859971372845099\ \(0\)\
\-\ involves\\:\\ 0\\.018451592395612372\ \(0\)\
\-\ tubular\\:\\ 0\\.018422663427579204\ \(0\)\
\-\ light\\:\\ 0\\.01836547224366082\ \(0\)\
\-\ require\\:\\ 0\\.018226229237544318\ \(0\)\
\-\ discharged\\:\\ 0\\.018198995755803485\ \(0\)\
\-\ component\\:\\ 0\\.018171960337500456\ \(0\)\
\-\ started\\:\\ 0\\.01786200141070999\ \(0\)\
\-\ even\\:\\ 0\\.017837301295705047\ \(0\)\
\-\ so\\:\\ 0\\.017837301295705047\ \(0\)\
\-\ strength\\:\\ 0\\.017764170669064917\ \(0\)\
\-\ clinically\\:\\ 0\\.01762208890478716\ \(0\)\
\-\ per\\:\\ 0\\.017598927748045345\ \(0\)\
\-\ their\\:\\ 0\\.017598927748045345\ \(0\)\
\-\ mixed\\:\\ 0\\.017553033910417338\ \(0\)\
\-\ indicated\\:\\ 0\\.017440718610830103\ \(0\)\
\-\ using\\:\\ 0\\.017440718610830103\ \(0\)\
\-\ 100\\:\\ 0\\.017396725746719105\ \(0\)\
\-\ atypical\\:\\ 0\\.017396725746719105\ \(0\)\
\-\ round\\:\\ 0\\.017374923023623513\ \(0\)\
\-\ total\\:\\ 0\\.017374923023623513\ \(0\)\
\-\ cranial\\:\\ 0\\.017331697494355057\ \(0\)\
\-\ via\\:\\ 0\\.017331697494355057\ \(0\)\
\-\ bleeding\\:\\ 0\\.017331697494355057\ \(0\)\
\-\ test\\:\\ 0\\.017246725711768565\ \(0\)\
\-\ four\\:\\ 0\\.01718424770946\ \(0\)\
\-\ before\\:\\ 0\\.017143171560784244\ \(0\)\
\-\ linear\\:\\ 0\\.01708239603326225\ \(0\)\
\-\ general\\:\\ 0\\.017022598170674332\ \(0\)\
\-\ outside\\:\\ 0\\.017022598170674332\ \(0\)\
\-\ caused\\:\\ 0\\.017002877415502948\ \(0\)\
\-\ appearing\\:\\ 0\\.016944335203537168\ \(0\)\
\-\ condition\\:\\ 0\\.016944335203537168\ \(0\)\
\-\ references\\:\\ 0\\.01690581305951805\ \(0\)\
\-\ nodular\\:\\ 0\\.01688670065941414\ \(0\)\
\-\ al\\:\\ 0\\.01684876815036041\ \(0\)\
\-\ especially\\:\\ 0\\.016774044958413593\ \(0\)\
\-\ not\\:\\ 0\\.01674256788059037\ \(0\)\
\-\ initially\\:\\ 0\\.01662895908511028\ \(0\)\
\-\ et\\:\\ 0\\.016611215120004897\ \(0\)\
\-\ full\\:\\ 0\\.016575979276743348\ \(0\)\
\-\ 80\\:\\ 0\\.01654107429135497\ \(0\)\
\-\ placed\\:\\ 0\\.016523743940005945\ \(0\)\
\-\ considered\\:\\ 0\\.016523743940005945\ \(0\)\
\-\ evaluate\\:\\ 0\\.016489323753057384\ \(0\)\
\-\ vessels\\:\\ 0\\.016455219352090832\ \(0\)\
\-\ filling\\:\\ 0\\.016421424995423255\ \(0\)\
\-\ persistent\\:\\ 0\\.01633825925312029\ \(0\)\
\-\ single\\:\\ 0\\.01630550702687547\ \(0\)\
\-\ progressive\\:\\ 0\\.016240855768947272\ \(0\)\
\-\ extremities\\:\\ 0\\.016114831712711962\ \(0\)\
\-\ related\\:\\ 0\\.016114831712711962\ \(0\)\
\-\ note\\:\\ 0\\.015963081923136734\ \(0\)\
\-\ film\\:\\ 0\\.01584599023875596\ \(0\)\
\-\ its\\:\\ 0\\.01569078405317951\ \(0\)\
\-\ hospital\\:\\ 0\\.01566324797444507\ \(0\)\
\-\ confirmed\\:\\ 0\\.015635914368709047\ \(0\)\
\-\ greater\\:\\ 0\\.015622322566980243\ \(0\)\
\-\ throughout\\:\\ 0\\.015595287148677212\ \(0\)\
\-\ clear\\:\\ 0\\.01537309444165977\ \(0\)\
\-\ abnormalities\\:\\ 0\\.015360428829299798\ \(0\)\
\-\ diagnosed\\:\\ 0\\.015360428829299798\ \(0\)\
\-\ intact\\:\\ 0\\.015347806224195312\ \(0\)\
\-\ presence\\:\\ 0\\.015236091030127427\ \(0\)\
\-\ venous\\:\\ 0\\.01513953096141611\ \(0\)\
\-\ heart\\:\\ 0\\.014744296004776643\ \(0\)\
\-\ underwent\\:\\ 0\\.01460757452063676\ \(0\)\
\-\ given\\:\\ 0\\.014586979710998262\ \(0\)\
\-\ although\\:\\ 0\\.01443605152682621\ \(0\)\
\-\ less\\:\\ 0\\.014426204226679706\ \(0\)\
\-\ size\\:\\ 0\\.014357993989416463\ \(0\)\
\-\ first\\:\\ 0\\.014310027470590899\ \(0\)\
\-\ initial\\:\\ 0\\.014225217245345163\ \(0\)\
\-\ unremarkable\\:\\ 0\\.014215912225138705\ \(0\)\
\-\ plain\\:\\ 0\\.013990549067070653\ \(0\)\
\-\ often\\:\\ 0\\.013836351003857461\ \(0\)\
\-\ should\\:\\ 0\\.013836351003857461\ \(0\)\
\-\ further\\:\\ 0\\.013811261907733262\ \(0\)\
\-\ between\\:\\ 0\\.013778071029811547\ \(0\)\
\-\ any\\:\\ 0\\.013704457661318718\ \(0\)\
\-\ 20\\:\\ 0\\.013680240288166475\ \(0\)\
\-\ such\\:\\ 0\\.013640225330942831\ \(0\)\
\-\ medical\\:\\ 0\\.01347671326325411\ \(0\)\
\-\ some\\:\\ 0\\.013342066018088782\ \(0\)\
\-\ her\\:\\ 0\\.013247767113456614\ \(0\)\
\-\ only\\:\\ 0\\.013247767113456614\ \(0\)\
\-\ decreased\\:\\ 0\\.013134897611706515\ \(0\)\
\-\ negative\\:\\ 0\\.01312795577284231\ \(0\)\
\-\ evaluation\\:\\ 0\\.012932082573471837\ \(0\)\
\-\ lung\\:\\ 0\\.012899330347227017\ \(0\)\
\-\ when\\:\\ 0\\.012809130166519547\ \(0\)\
\-\ infection\\:\\ 0\\.012809130166519547\ \(0\)\
\-\ weeks\\:\\ 0\\.012708655033063506\ \(0\)\
\-\ through\\:\\ 0\\.012622913256971771\ \(0\)\
\-\ all\\:\\ 0\\.012622913256971771\ \(0\)\
\-\ include\\:\\ 0\\.012616863859979295\ \(0\)\
\-\ two\\:\\ 0\\.012592764238252695\ \(0\)\
\-\ he\\:\\ 0\\.012556905243488284\ \(0\)\
\-\ been\\:\\ 0\\.012354353390048329\ \(0\)\
\-\ if\\:\\ 0\\.012320711951113823\ \(0\)\
\-\ lesions\\:\\ 0\\.012178351116708572\ \(0\)\
\-\ evidence\\:\\ 0\\.012036067911702199\ \(0\)\
\-\ common\\:\\ 0\\.0120257419227528\ \(0\)\
\-\ than\\:\\ 0\\.012020589664642485\ \(0\)\
\-\ who\\:\\ 0\\.011994934948384245\ \(0\)\
\-\ anterior\\:\\ 0\\.011839709754385305\ \(0\)\
\-\ over\\:\\ 0\\.011790988825890686\ \(0\)\
\-\ metastatic\\:\\ 0\\.011629957249641807\ \(0\)\
\-\ abdominal\\:\\ 0\\.011597652297208093\ \(0\)\
\-\ consistent\\:\\ 0\\.011497912436193062\ \(0\)\
\-\ bilateral\\:\\ 0\\.011396423481723804\ \(0\)\
\-\ imaging\\:\\ 0\\.011144017483581604\ \(0\)\
\-\ tissue\\:\\ 0\\.011123737271625906\ \(0\)\
\-\ most\\:\\ 0\\.011035795772716487\ \(0\)\
\-\ present\\:\\ 0\\.010881044868911735\ \(0\)\
\-\ lower\\:\\ 0\\.010835848523336114\ \(0\)\
\-\ exam\\:\\ 0\\.010674676916362816\ \(0\)\
\-\ after\\:\\ 0\\.010286959904649298\ \(0\)\
\-\ presents\\:\\ 0\\.010200765791456262\ \(0\)\
\-\ seen\\:\\ 0\\.009983207127758216\ \(0\)\
\-\ has\\:\\ 0\\.009685889028140876\ \(0\)\
\-\ male\\:\\ 0\\.009441343022181326\ \(0\)\
\-\ history\\:\\ 0\\.00810159017608743\ \(0\)\
\-\ at\\:\\ 0\\.008009448953223641\ \(0\)\
\-\ no\\:\\ 0\\.0068956694873464446\ \(0\)\
